Subscale | Group | Baseline score | One month after the onset of intervention | Two months after the onset of intervention | Between groups difference |
---|---|---|---|---|---|
Irritability | N-Acetylcysteine + risperidone | 13.2(5.3) | 10.0(4.1) | 9.7(4.1) | F1,29= 4.9, P<0.035 |
Placebo+Risperidone | 16.7(7.8) | 15.5(7.9) | 15.1(7.8) | ||
Hyperactivity and Noncompliance | N-Acetylcysteine + risperidone | 29.3(6.4) | 21.4(7.7) | 18.3(6.9) | F1,29= 2.4, P=0.12 |
Placebo+Risperidone | 31.9(8.9) | 26.8(11.0) | 24.3(12.1) | ||
Lethargy and Social Withdrawal | N-Acetylcysteine + risperidone | 11.9(6.5) | 9.0(5.7) | 8.5(6.5) | F1,28= 0.4, P=0.53 |
Placebo+Risperidone | 12.2(8.3) | 11.0(7.8) | 10.9(7.5)6 | ||
Stereotypic Behavior | N-Acetylcysteine + risperidone | 6.6(4.5) | 4.5(3.6) | 3.9(2.7) | F1,28= 2.8, P=0.1 |
Placebo+Risperidone | 8.5(6.3) | 7.7(6.2) | 7.8(6.6) | ||
Inappropriate Speech | N-Acetylcysteine + risperidone | 3.9(3.7) | 3.8(3.7) | 3.2(3.4) | F1,29= 1.8, P=0.1 |
Placebo+Risperidone | 5.7(3.8) | 5.3(3.7) | 5.2(4.0) |